Completed PHASE1 INTERVENTIONAL 4-arm NCT05847218

Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers

A Single-Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics of RHN-001 in Healthy Adult Volunteers.

Sponsor: Center for Bioequivalence Studies and Clinical Research

Conditions Pharmacokinetics Safety Tolerability

Interventions RHN-001 (750mg * 2 Tablets) RHN-001 (one tablet 750mg)

Updated 3 times since 2023 Last updated: Apr 26, 2023 Started: Mar 9, 2023 Primary completion: Mar 19, 2023 Completion: Mar 19, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05847218, this PHASE1 trial focuses on Pharmacokinetics and Safety and remains completed. Sponsored by Center for Bioequivalence Studies and Clinical Research, it has been updated 3 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2023 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Center for Bioequivalence Studies and Clinical Research
RH Nanopharmaceuticals

Data source: RH Nanopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karachi, Pakistan